Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

p38 MAPK

p38 MAPKs (α, β, γ, and δ) are members of the MAPK family that are activated by a variety of environmental stresses and inflammatory cytokines. As with other MAPK cascades, the membrane-proximal component is a MAPKKK, typically a MEKK or a mixed lineage kinase (MLK). The MAPKKK phosphorylates and activates MKK3/6, the p38 MAPK kinases. MKK3/6 can also be activated directly by ASK1, which is stimulated by apoptotic stimuli. p38 MAPK is involved in regulation of HSP27, MAPKAPK-2 (MK2), MAPKAPK-3 (MK3), and several transcription factors including ATF-2, Stat1, the Max/Myc complex, MEF-2, Elk-1, and indirectly CREB via activation of MSK1.

Emprumapimod
T63067765914-60-1In house
Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
  • $263
In Stock
Size
QTY
SB 202190
T2301152121-30-7
SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.
  • $35
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
SSK1
T374502629250-69-5In house
SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3 MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
  • $215 TargetMol
In Stock
Size
QTY
Adezmapimod
T1764152121-47-6
Adezmapimod (SB 203580) is a selective, ATP-competitive p38 MAPK inhibitor (IC50=0.3-0.5 μM) that activates autophagy and mitochondrial autophagy, with more than 100-fold higher selectivity over PKB, LCK, and GSK-3β.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
UM-164
T4597903564-48-7
UM-164 (DAS-DFGO-II), a highly potent c-Src inhibitor with a dissociation constant (Kd) of 2.7 nM, also effectively inhibits p38α and p38β.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
JNJ-49095397
T729181220626-82-3In house
JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory syncytial virus infection.
  • $88
In Stock
Size
QTY
EO-1606
T31645344457-87-0In house
EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.
  • $293 TargetMol
In Stock
Size
QTY
Vincristine
T3S020957-22-7
Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine can be used as a microtubule-destabilizing agent for research on the treatment of hematologic cancers, such as leukemia and
  • $148
In Stock
Size
QTY
MW-150
T54941628502-91-9
MW-150 (MW01-18-150SRM) is a unique, selective, CNS-penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM.
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
AKP-001
T25015897644-83-6In house
AKP-001 is a selective inhibitor of MAPK of the p38α isoform and is used in the study of immune and digestive disorders.
  • $1,520
In Stock
Size
QTY
SB 242235
T4078193746-75-7
SB 242235 is a potent and selective p38 MAP kinase inhibitor that may be an effective therapy for cytokine-mediated diseases.
  • $40
In Stock
Size
QTY
UR13870
T29071755753-89-0In house
UR-13870 (Org 48762-0) is an orally active and selective inhibitor of p38 mitogen-activated protein kinase (MAPK), which prevents bone damage in collagen-induced arthritis in mice.
  • $228 TargetMol
In Stock
Size
QTY
Doramapimod
T6277285983-48-4
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
p38 MAPK Inhibitor
T36010219138-24-6In house
p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.
  • $88
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Exarafenib
T636442639957-39-2
Exarafenib (RAF KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.
  • $131
In Stock
Size
QTY
Ciglitazone
T1971074772-77-3
Ciglitazone (ADD 3878) is a potent and selective PPARγ agonist (EC50: 3 μM) and oral hypoglycemic agent. Ciglitazone inhibits proliferation and differentiation of th17 cells, decreases insulin levels, vascular endothelial growth factor production and blood pressure, and induces cell cycle arrest in gastric cancer cells. Selegiline induces apoptosis in opossum kidney epithelial cells and activates nuclear translocation of p38 MAPK and apoptosis-inducing factor (AIF). Ciglitazone exhibits hypoglycaemic activity in animal models of obesity and hyperglycaemia.
  • $91
In Stock
Size
QTY
SU9516
T6167377090-84-1
SU9516 is a potent CDK2 inhibitor with an IC50 of 22 nM and also inhibits CDK1 and CDK4, with IC50s of 40 nM and 200 nM, respectively.
  • $30
In Stock
Size
QTY
Talmapimod
T12871309913-83-5In house
Talmapimod (SCIO-469) is a selective, orally active, ATP-competitive p38α inhibitor with IC50 values of 9 nM for p38α and 90 nM for p38β. Talmapimod exhibits at least 2000-fold selectivity over a panel of 20 kinases, including other MAPKs.
  • $48
In Stock
Size
QTY
PH-797804
T1974586379-66-0
PH-797804 is a pyridinone inhibitor of p38α (IC50: 26 nM, in a cell-free assay); 4-fold more selective versus p38β and does not inhibit JNK2.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PF-3644022
T165011276121-88-0
PF-3644022 is an effective, selective, and ATP-competitive MAPKAPK2 (MK2) inhibitor (IC50: 5.2 nM and a Ki of 3 nM). PF-3644022 potently inhibits TNFα production and has an anti-inflammatory effect. PF-3644022 also inhibits MK3 and p38 regulated activated
  • $31
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Gypenoside L
TN172194987-09-4
Gypenoside L inhibits autophagic flux and induces cell death in human esophageal cancer cells through endoplasm reticulum stress-mediated Ca2+ release. It also inhibit non-small cell lung carcinoma A549 cell inhibitory activity.
  • $128
In Stock
Size
QTY
PD 169316
T2432152121-53-4
PD 169316 is a potent, cell-permeable, and selective inhibitor of p38 MAP kinase.
  • $48
In Stock
Size
QTY
TargetMol | Citations Cited
Iroxanadine
T27627203805-20-3In house
Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.CAS 번호13480-84-5
  • $146
In Stock
Size
QTY
SGX-523
T22931022150-57-7
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
AMG 900
T6380945595-80-2
AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A B C with IC50 values of 5 nM, 4 nM, and 1 nM, respectively. It exhibits over 10-fold selectivity for Aurora kinases compared to p38α, Tyk2, JNK2, Met, and Tie2. [Phase 1].
  • $44
In Stock
Size
QTY
ITX5061
T156031252679-52-9
ITX5061 is a type II inhibitor of p38 MAPK and an antagonist of scavenger receptor B1 (SRB1), used for studying hepatitis C virus infection.
  • $215
In Stock
Size
QTY
EM 163
T411421206480-93-4In house
EM 163 is a TIR-TIR interaction inhibitor, which is a TIR (Toll interleukin-1 receptor) structural domain mimic of the MyD88 protein. EM 163 targets the TIR structural domain in the IL-1 receptor and blocks the interaction with MyD88. EM 163 inhibits the production of inflammatory cytokines in vivo caused by staphylococcal enterotoxin B (SEB). EM 163 protects mice from SEB shock-induced death. In rat hippocampal neurons in vitro, EM 163 blocked the activation of p38 and the inhibitory effect of IL-1β on chemically induced long-term potentiation (LTP)-triggered protein synthesis.
  • $123
In Stock
Size
QTY
AZD7624
T143811095004-78-6
AZD7624 is an p38 inhibitor. It has potent anti-inflammatory activity.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Ralimetinib dimesylate
T6047862507-23-1
Ralimetinib dimesylate (LY2228820 dimesylate) is the dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities.
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
MAPK13-IN-1
T11943229002-10-2
MAPK13-IN-1 is a potent MAPK13 (p38δ) inhibitor (IC50: 620 nM).
  • $100
In Stock
Size
QTY
Pexmetinib
T6934945614-12-0
Pexmetinib (ARRY-614) is an orally bioavailable dual p38 MAPK Tie-2 inhibitor studied in acute myeloid leukemia and inhibits osteoclastogenesis and breast cancer-induced osteolysis via the P38 STAT3 signaling pathway.
  • $54
In Stock
Size
QTY
Skepinone-L
T61301221485-83-1
Skepinone-L (CBS3830) is a selective inhibitor of p38 mitogen-activated protein kinase.
  • $32
In Stock
Size
QTY
Neflamapimod
T6089209410-46-8
Neflamapimod (VX-745) , a specific and effective inhibitor of p38α(IC50=10 nM), is 22-fold greater specificity against p38β and no inhibition activity to p38γ.
  • $43
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PP58
T13824212391-58-7
PP58 is an inhibitor of PDGFR, FGFR and Src family.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Pamapimod
T6927449811-01-2
Pamapimod (R1503) (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase. It inhibits p38α and p38β enzymatic activity with IC50 values of 0.014±0.002 and 0.48± 0.04 microM, respectively with no activity against p38delta or p38 gamma isoforms.
  • $51
In Stock
Size
QTY
Dilmapimod
T12850444606-18-2
Dilmapimod (SB-681323) is a potent inhibitor of p38 MAPK, potentially suppressing inflammation in chronic obstructive pulmonary disease.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TAK-715
T6150303162-79-0
TAK-715 is a p38 MAPK inhibitor for p38α.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
SB 239063
T6976193551-21-2
SB 239063 (SB239063) is a potent and selective p38 MAPKα β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
  • $43
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SD 0006
T7276271576-80-8
SD 0006 (SD-06) is a MAPK p38 alpha inhibitor with an IC50 of 110 nM, indicated for the treatment of arthritis.
  • $32
In Stock
Size
QTY
TargetMol | Inhibitor Sale
p38-α MAPK-IN-1
T12347443913-15-3
p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor with an IC50 of 2300 nM in the EFC displacement assay and 5500 nM in the HTRF assay.
  • $53
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BMS582949
T6789623152-17-0
BMS-582949 is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13 nM, inhibiting both p38 kinase activity and activation of p38.
  • $47
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
VX-702
T2513745833-23-2In house
VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).
  • $50
In Stock
Size
QTY
SB 203580 hydrochloride
T21675869185-85-3
SB 203580 hydrochloride (Adezmapimod hydrochloride) is a selective, ATP-competitive p38 MAPK inhibitor that induces mitochondrial autophagy and cytosolic autophagy and inhibits SAPK2a p38, SAPK2b p38β2, LCK, GSK3β, and PKBα. SB 203580 hydrochloride has been shown to be useful in antiretroviral therapy. 203580 hydrochloride inhibits amphoteric mechanical anomalous pain in a mouse model of antiretroviral-induced neuropathic pain.
  • $36
In Stock
Size
QTY
RWJ-67657
T16812215303-72-3
RWJ-67657 (JNJ 3026582) is an orally active, selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively), with no activity at p38γ and p38δ, and demonstrates cardioprotective effects.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CK1-IN-1
T53931784751-20-7
CK1-IN-1 (PUN51207) is a casein kinase 1 (CK1) inhibitor. CK1-IN-1 has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.
  • $42
In Stock
Size
QTY
TargetMol | Inhibitor Sale
p38 MAP Kinase Inhibitor Ⅵ
T67944421578-46-3
p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.
  • $77
In Stock
Size
QTY
SC-514
T2118354812-17-2
SC-514 (GK 01140) is a selective, orally active, ATP-competitive IKK-2 inhibitor (IC50=11.2±4.7 μM), obstructs NF-κB-dependent gene expression.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
BMS-582949 hydrochloride
T3462912806-16-7
The BMS-582949 hydrochloride (BMS-582949 HCl) is a highly specific p38α MAPK inhibitor (IC50: 13 nM).
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale